Raymond James Financial
XLO icon

Raymond James Financial’s Xilio Therapeutics XLO Stock Holding History

Raymond James Financial’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,340
Closed -$12K – 5465
2025
Q4 		$12K Hold
1,340
– – ﹤0.01% 5124
2025
Q3 		$15.8K Hold
1,340
– – ﹤0.01% 4918
2025
Q2 		$12.8K Sell
1,340
-1,086
-45% -$11.5K ﹤0.01% 5811
2025
Q1 		$24.6K Sell
2,426
-1,152
-32% -$14.5K ﹤0.01% 4701
2024
Q4 		$47.8K Buy
+3,578
New +$49.2K ﹤0.01% 4615

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial's XLO Position: Q1 2026 in Review

Raymond James Financial sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 1,340 shares — an estimated $12K sold.

Raymond James Financial first reported a position in XLO in Q4 2024 and held it in 5 quarters. The position peaked at $47.8K in Q4 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Raymond James Financial reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 1,340 Xilio Therapeutics shares in Q1 2026, an estimated $12K.
  • Raymond James Financial first reported a position in Xilio Therapeutics in Q4 2024 and held it in 5 quarters.
  • Raymond James Financial's Xilio Therapeutics position peaked at $47.8K in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.